TOPICAL BACITRACIN THERAPY OF PYOGENIC DERMATOSES
A Clinical Report
Since this article does not have an abstract, we have provided the first 150 words of the full text.
Excerpt
The literature is replete with evidence of the high index of allergenicity of the more effective agents used in the therapy of the various pyodermas. The alarming incidence of the apparent induction of hypersensitivity to such valuable medicaments as sulfonamide drugs and penicillin when they are used topically to treat the minor dermatoses, thus vitiating their future usefulness in generalized and systemic infections, has prompted the cautioning editorial by Sulzberger and Baer in the "Year Book of Dermatology."1 It is therefore expedient that information concerning the useful and less allergenic therapeutic agents be promulgated widely. We are reporting some significant clinical results which we have noted following the topical administration of a new antibiotic, bacitracin. These results corroborate the findings of Miller, Slatkin and Johnson reported recently in the Journal of Investigative Dermatology.2
HISTORICAL DATA In Science (Oct. 12, 1945) Johnson, Anker and Meleney3 reported the recovery
Footnotes
-
Bacitracin used in this study was donated by Commercial Solvents Corporation, New York.
-
Instructor in Dermatology, Georgetown University School of Medicine, and attending staff physician, Walter Reed General Hospital (Dr. Derzavis).
-
The opinions expressed are those of the authors and are not to be considered the official opinion of the medical department of the United States Army.
-
Clinical studies herein reported were carried out at the Walter Reed General Hospital and in the Division of Dermatology, Georgetown University Service, Gallinger Municipal Hospital.
